These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 14506034)

  • 1. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.
    Komp Lindgren P; Karlsson A; Hughes D
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3222-32. PubMed ID: 14506034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.
    Komp Lindgren P; Marcusson LL; Sandvang D; Frimodt-Møller N; Hughes D
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2343-51. PubMed ID: 15917531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
    Ozeki S; Deguchi T; Yasuda M; Nakano M; Kawamura T; Nishino Y; Kawada Y
    J Clin Microbiol; 1997 Sep; 35(9):2315-9. PubMed ID: 9276409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and mechanism of fluoroquinolone resistance in Escherichia coli isolated from swine farms in China.
    Cheng P; Yang Y; Li F; Li X; Liu H; Fazilani SA; Guo W; Xu G; Zhang X
    BMC Vet Res; 2020 Jul; 16(1):258. PubMed ID: 32723358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
    Drago L; Nicola L; Mattina R; De Vecchi E
    BMC Microbiol; 2010 Apr; 10():119. PubMed ID: 20409341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of fluoroquinolone-resistant Escherichia coli strains isolated from urine clinical samples.
    Dehbanipour R; Khanahmad H; Sedighi M; Bialvaei AZ; Faghri J
    J Prev Med Hyg; 2019 Mar; 60(1):E25-E30. PubMed ID: 31041407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
    Gales AC; Gordon KA; Wilke WW; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):61-4. PubMed ID: 10744370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
    Ling JM; Chan EW; Lam AW; Cheng AF
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3567-73. PubMed ID: 14576119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.
    Sorlozano A; Gutierrez J; Jimenez A; de Dios Luna J; Martínez JL
    J Clin Microbiol; 2007 Aug; 45(8):2740-2. PubMed ID: 17567787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity and Mechanisms of Fluoroquinolone Resistance within the H30 and H30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli.
    Johnson JR; Johnston B; Kuskowski MA; Sokurenko EV; Tchesnokova V
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4471-80. PubMed ID: 25987621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
    Nathania I; Nainggolan IM; Yasmon A; Nusatia ACM; Tjoa E; Gunardi WD; Moehario LH
    BMC Microbiol; 2022 Oct; 22(1):250. PubMed ID: 36253712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.